Cindy Neuzillet1,2,3, Anne Couvelard1,3,4, Annemilaï Tijeras-Raballand5, Louis de Mestier1, Armand de Gramont6, Pierre Bédossa1,3,4, Valérie Paradis1,3,4, Alain Sauvanet3,7, Jean-Baptiste Bachet8, Philippe Ruszniewski1,3,9, Eric Raymond6, Pascal Hammel1,2,3, Jérôme Cros1,3,4. 1. INSERM UMR1149. 2. Department of Digestive Oncology, Beaujon University Hospital, Clichy, France. 3. Paris 7 Denis Diderot University, Paris, France. 4. Department of Pathology, Bichat-Beaujon University Hospital, Paris-Clichy, France. 5. Department of Translational Research, AAREC Filia Research, Boulogne-Billancourt, France. 6. Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 7. Department of Biliary and Pancreatic Surgery, Beaujon University Hospital, Clichy, France. 8. Department of Gastroenterology, Pitié-Salpêtrière University Hospital, Paris, France. 9. Department of Gastroenterology and Pancreatology, Beaujon University Hospital, Clichy, France.
Abstract
AIMS: c-Met is an emerging biomarker in pancreatic ductal adenocarcinoma (PDAC); there is no consensus regarding the immunostaining scoring method for this marker. We aimed to assess the prognostic value of c-Met overexpression in resected PDAC, and to elaborate a robust and reproducible scoring method for c-Met immunostaining in this setting. METHODS AND RESULTS: c-Met immunostaining was graded according to the validated MetMab score, a classic visual scale combining surface and intensity (SI score), or a simplified score (high c-Met: ≥ 20% of tumour cells with strong membranous staining), in stage I-II PDAC. A computer-assisted classification method (Aperio software) was developed. Clinicopathological parameters were correlated with disease-free survival (DFS) and overall survival(OS). One hundred and forty-nine patients were analysed retrospectively in a two-step process. Thirty-seven samples (whole slides) were analysed as a pre-run test. Reproducibility values were optimal with the simplified score (kappa = 0.773); high c-Met expression (7/37) was associated with shorter DFS [hazard ratio (HR) 3.456, P = 0.0036] and OS (HR 4.257, P = 0.0004). c-Met expression was concordant on whole slides and tissue microarrays in 87.9% of samples, and quantifiable with a specific computer-assisted algorithm. In the whole cohort (n = 131), patients with c-Met(high) tumours (36/131) had significantly shorter DFS (9.3 versus 20.0 months, HR 2.165, P = 0.0005) and OS (18.2 versus 35.0 months, HR 1.832, P = 0.0098) in univariate and multivariate analysis. CONCLUSIONS: Simplified c-Met expression is an independent prognostic marker in stage I-II PDAC that may help to identify patients with a high risk of tumour relapse and poor survival.
AIMS: c-Met is an emerging biomarker in pancreatic ductal adenocarcinoma (PDAC); there is no consensus regarding the immunostaining scoring method for this marker. We aimed to assess the prognostic value of c-Met overexpression in resected PDAC, and to elaborate a robust and reproducible scoring method for c-Met immunostaining in this setting. METHODS AND RESULTS:c-Met immunostaining was graded according to the validated MetMab score, a classic visual scale combining surface and intensity (SI score), or a simplified score (high c-Met: ≥ 20% of tumour cells with strong membranous staining), in stage I-II PDAC. A computer-assisted classification method (Aperio software) was developed. Clinicopathological parameters were correlated with disease-free survival (DFS) and overall survival(OS). One hundred and forty-nine patients were analysed retrospectively in a two-step process. Thirty-seven samples (whole slides) were analysed as a pre-run test. Reproducibility values were optimal with the simplified score (kappa = 0.773); high c-Met expression (7/37) was associated with shorter DFS [hazard ratio (HR) 3.456, P = 0.0036] and OS (HR 4.257, P = 0.0004). c-Met expression was concordant on whole slides and tissue microarrays in 87.9% of samples, and quantifiable with a specific computer-assisted algorithm. In the whole cohort (n = 131), patients with c-Met(high) tumours (36/131) had significantly shorter DFS (9.3 versus 20.0 months, HR 2.165, P = 0.0005) and OS (18.2 versus 35.0 months, HR 1.832, P = 0.0098) in univariate and multivariate analysis. CONCLUSIONS: Simplified c-Met expression is an independent prognostic marker in stage I-II PDAC that may help to identify patients with a high risk of tumour relapse and poor survival.
Authors: Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488
Authors: W Li; M Hu; C Wang; H Lu; F Chen; J Xu; Y Shang; F Wang; J Qin; Q Yan; B J Krueger; R Renne; S-J Gao; C Lu Journal: Oncogene Date: 2017-05-22 Impact factor: 9.867
Authors: Joshua B N Dawkins; Jun Wang; Eleni Maniati; James A Heward; Lola Koniali; Hemant M Kocher; Sarah A Martin; Claude Chelala; Frances R Balkwill; Jude Fitzgibbon; Richard P Grose Journal: Cancer Res Date: 2016-06-08 Impact factor: 12.701